LSTA
Lisata Therapeutics, Inc. (LSTA) ESG Analysis Analysis (2026)
Overall Score
Environmental
No material environmental disclosures or sustainability metrics were provided in the fresh data.
The company’s capital intensity appears low in the reported TTM figures, with capex-to-revenue at 0 and capex-to-operating cash flow at 0, but this is not enough to establish a strong environmental profile.
Social
No material workforce, customer, or community ESG disclosures were provided in the fresh data.
Very high SG&A and R&D ratios relative to revenue suggest a heavy operating burden, but the data do not provide enough evidence to translate this into a positive social score.
Governance
No material governance disclosures, board changes, or controversy news were provided in the fresh data.
The balance sheet shows no debt in the reported ratios, which supports a cleaner capital structure, but the company’s very weak profitability and cash generation limit governance confidence.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lisata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

